Salome
Laurence Salome, Auzeville Tolosane FR
Patent application number | Description | Published |
---|---|---|
20130157877 | BIOCHIPS FOR ANALYZING NUCLEIC ACID MOLECULE DYNAMICS - The invention relates to biochips | 06-20-2013 |
Marcelo Miguel Salome, Joinville BR
Patent application number | Description | Published |
---|---|---|
20150102542 | TUNED VIBRATION NEUTRALIZER DEVICE - The present invention relates to a vibration neutralizer designed, more specifically, for use in refrigeration compressors, especially aimed at reducing noises and vibrations derived from the operation of the compressor motor used in the refrigeration equipment. It basically comprises at least one rod ( | 04-16-2015 |
Margaret Salome, Amsterdam NL
Patent application number | Description | Published |
---|---|---|
20160132482 | AUTOMATIC ONTOLOGY GENERATION FOR NATURAL-LANGUAGE PROCESSING APPLICATIONS - A method of generating ontologies for a Virtual Assistant across different languages may include extracting a plurality of tokens in a first language from a plurality of web resources in a web domain that includes the Virtual Assistant. The web resources may be made available in a first language and a second language. The method may also include determining a first part-of-speech (POS) for each of the plurality of tokens, where the first POS may be specific to the first language. The method may additionally include mapping the first POS to a second POS from a standardized set of POS's that are general across the first language and the second language, and generating a plurality of lemmas from the plurality of tokens. The method may further include displaying a network representing the ontology. | 05-12-2016 |
Nathalie Salome, Dossenheim DE
Patent application number | Description | Published |
---|---|---|
20130189265 | MODIFIED PARVOVIRUS HAVING ENHANCED ANTI-TUMOR EFFICACY - Described are parvovirus variants derived, e.g., from H-1PV, showing higher anti-tumor potential compared to the wild type parvovirus, wherein said variant is characterized by (a) an amino acid substitution, alteration or addition, preferably substitution at position Lys96 of NS-2 and/or position Leu103 of NS-2 (together with a amino acid substituion at position Tyr595 of NS-1 in the latter case), or (b) an in-frame deletion in the parvovirus genome, preferably a deletion resulting in a large amino acid deletion in both the central part (aa 96-133) of NS-2 and the C-terminal part (aa 587-624) of NS-1. The present invention also relates to the use of said parvovirus variants for cancer therapy. | 07-25-2013 |